ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cachexia affects the majority of patients with advanced cancer and is associated with reduced treatment tolerance, response to therapy, quality of life, and life expectancy. Cachectic patients with advanced cancer often receive anti-cancer therapies against their specific cancer type as a standard of care, and whether specific ActRII inhibition is efficacious when combined with anti-cancer agents has not been elucidated yet. METHODS: In this study, we evaluated interactions between ActRII blockade and anti-cancer agents in CT-26 mouse colon cancer-induced cachexia model. CDD866 (murinized version of bimagrumab) is a neutralizing antibody against the activin receptor type II (ActRII) preventing binding of ligands such as myostatin and activin A, which are involved in cancer cachexia. CDD866 was evaluated in association with cisplatin as a standard cytotoxic agent or with everolimus, a molecular-targeted agent against mammalian target of rapamycin (mTOR). In the early studies, the treatment effect on cachexia was investigated, and in the additional studies, the treatment effect on progression of cancer and the associated cachexia was evaluated using body weight loss or tumor volume as interruption criteria. RESULTS: Cisplatin accelerated body weight loss and tended to exacerbate skeletal muscle loss in cachectic animals, likely due to some toxicity of this anti-cancer agent. Administration of CDD866 alone or in combination with cisplatin protected from skeletal muscle weight loss compared to animals receiving only cisplatin, corroborating that ActRII inhibition remains fully efficacious under cisplatin treatment. In contrast, everolimus treatment alone significantly protected the tumor-bearing mice against skeletal muscle weight loss caused by CT-26 tumor. CDD866 not only remains efficacious in the presence of everolimus but also showed a non-significant trend for an additive effect on reversing skeletal muscle weight loss. Importantly, both combination therapies slowed down time-to-progression. CONCLUSIONS: Anti-ActRII blockade is an effective intervention against cancer cachexia providing benefit even in the presence of anti-cancer therapies. Co-treatment comprising chemotherapies and ActRII inhibitors might constitute a promising new approach to alleviate chemotherapy- and cancer-related wasting conditions and extend survival rates in cachectic cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of myostatin activity and muscle growth
Lee, S.-J., & McPherron, A. C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151270098 · Cited by 1,616
Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child
Schuelke, M., Wagner, K. R., Stolz, L. E., Hübner, C., Riebel, T., Kömen, W., Braun, T., Tobin, J. F., & Lee, S.-J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040933 · Cited by 1,399
Bentzinger, C. F., Romanino, K., Cloëtta, D., Lin, S., Mascarenhas, J. B., Oliveri, F., Xia, J., Casanova, E., Costa, C. F., Brink, M., et al. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2008.10.002 · Cited by 640 · cited 1×
“Interestingly, ActRII inhibition by CDD866 not only remained efficacious in the presence of everolimus but also showed a nonsignificant trend for an additive effect at reversing skeletal muscle weight loss, despite the fact that mTOR is required for normal muscle growth [21, 22].”
BackgroundKhamzina, L., Veilleux, A., Bergeron, S., & Marette, A. (2005) · Endocrinology · doi:10.1210/en.2004-0921 · Cited by 562 · cited 1×
“Activation of mTOR is also reported in other pathological conditions, such as aging [27], obesity, insulin resistance, and diabetes [28], where mTOR inhibition seems to be beneficial [29].”
BackgroundRegulation of muscle growth by multiple ligands signaling through activin type II receptors
Lee, S.-J., Reed, L. A., Davies, M. V., Girgenrath, S., Goad, M. E. P., Tomkinson, K. N., Wright, J. F., Barker, C., Ehrmantraut, G., Holmstrom, J., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0505996102 · Cited by 501
Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy
Risson, V., Mazelin, L., Roceri, M., Sanchez, H., Moncollin, V., Corneloup, C., Richard-Bulteau, H., Vignaud, A., Baas, D., Defour, A., et al. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200903131 · Cited by 381
Lach-Trifilieff, E., Minetti, G. C., Sheppard, K., Ibebunjo, C., Feige, J. N., Hartmann, S., Brachat, S., Rivet, H., Koelbing, C., Morvan, F., et al. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01307-13 · Cited by 306 · cited 2×
“In this report, the effect of a chimeric mouse version of bimagrumab (CDD866) [17], which retains the binding, selectivity, and potency profile of bimagrumab while reducing risk for immunogenicity and enabling longterm profiling studies in mice, was evaluated in a CT-26 mouse colon cancer cachexia model to clarify int…”
BackgroundSelf-citationTreatment of sporadic inclusion body myositis with bimagrumab
Amato, A. A., Sivakumar, K., Goyal, N., David, W. S., Salajegheh, M., Praestgaard, J., Lach-Trifilieff, E., Trendelenburg, A.-U., Laurent, D., Glass, D. J., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001070 · Cited by 210
Self-citationAntibody-Directed Myostatin Inhibition Enhances Muscle Mass and Function in Tumor-Bearing Mice
Murphy, K. T., Chee, A., Gleeson, B. G., Naim, T., Swiderski, K., Koopman, R., & Lynch, G. S. (2011) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00121.2011 · Cited by 111 · cited 2×
“Together with data demonstrating that blockade of the myostatin/ActRIIB pathway is highly beneficial in models of cancer-induced cachexia [3–6], our results indicate that ActRII blockade might be beneficial in cachectic cancer patients which are or have been exposed to chemotherapies.”
Background
Cited by
Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A., & Breit, S. N. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.07.018 · Cited by 409
Morvan, F., Rondeau, J.-M., Zou, C., Minetti, G., Scheufler, C., Scharenberg, M., Jacobi, C., Brebbia, P., Ritter, V., Toussaint, G., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707925114 · Cited by 142
Self-citationMyostatin and its Regulation: A Comprehensive Review of Myostatin Inhibiting Strategies
Baig, M. H., Ahmad, K., Moon, J. S., Park, S.-Y., Ho Lim, J., Chun, H. J., Qadri, A. F., Hwang, Y. C., Jan, A. T., Ahmad, S. S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.876078 · Cited by 135
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
Rodgers, B. D., & Ward, C. W. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab030 · Cited by 111
Myostatin: a skeletal muscle chalone
Lee, S.-J. (2023) · Annual Review of Physiology · doi:10.1146/annurev-physiol-012422-112116 · Cited by 84
Metadata
- Authors
- Hatakeyama, S., Summermatter, S., Jourdain, M., Melly, S., Minetti, G. C., & Lach-Trifilieff, E.
- Venue
- Skeletal Muscle
- Published
- 2016-07-26
- Volume
- 6
- Issue
- 1
- Pages
- 26-26
- ISSN
- 2044-5040 (ISSN-L)
- OpenAlex
- W2463253051
- Cited by
- 81
- References
- 9
- FWCI
- 6.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. https://app.cochat.ai/papers/10.1186/s13395-016-0098-2
- The paper
- Hatakeyama, S., Summermatter, S., Jourdain, M., Melly, S., Minetti, G. C., & Lach-Trifilieff, E. (2016). ActRII blockade protects mice from cancer cachexia and prolongs survival in the presence of anti-cancer treatments. Skeletal Muscle. https://doi.org/10.1186/s13395-016-0098-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.